Stock Financial Ratios, Dividends, Split History
VRTU / Virtusa Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||1,426.16|
|Enterprise Value ($M)||1,425.10|
|Book Value ($M)||418.62|
|Book Value / Share||14.10|
|Price / Book||2.95|
|NCAV / Share||-0.70|
|Price / NCAV||-72.84|
|Weighted Average Number Of Shares Outstanding Basic||29,397,350|
|Common Stock Shares Outstanding||29,589,093|
|Common Shares Outstanding||29,681,942|
|Weighted Average Number Of Diluted Shares Outstanding||29,397,350|
|Temporary Equity Shares Outstanding||108,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.01|
|Return on Assets (ROA)||0.01|
|Return on Equity (ROE)||0.02|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1207074|
|SIC 7371 - Computer Programming Services|
Stock splits are used by Virtusa Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Related News Stories
The technology world's most bruising battle for supremacy is taking place in China. And it could point to Big Tech's future everywhere else, too. (16-0)
BEIJING — Forget Google versus Facebook. Forget Uber versus Lyft. Forget Amazon versus … well, everybody. (17-0)
Please standby, we are about to begin. Good day, and welcome to the Virtusa Corporation Fiscal Fourth Quarter 2018 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Will Maina of ICR. Please go ahead sir. (1-0)
The following slide deck was published by Virtusa Corporation in conjunction with their 2018 Q4 earnings call. (1-0)
* VIRTUSA CORP - FOR Q4, MANAGEMENT CURRENTLY EXPECTS ETOUCH TO CONTRIBUTE REVENUE OF APPROXIMATELY $5.0 MILLION (1-0)
as of ET